Pancreatic Cancer Research

ResearcherKorea Advanced Institute of Science and TechnologyActive in the last 2 years

Soon‐Sun Hong

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7679-1388; OpenAlex author ID A5049018558. Sources: OpenAlex.

Their work

Papers
19 (first author 1, last author 16)
Trials
0
Grants
0
Labs led
1
Collaborators
28
Papers, trials and grants by year

2013: 3 papers · 2014: 2 papers · 2015: none · 2016: 1 paper · 2017: 3 papers · 2018: 3 papers · 2019: 1 paper · 2020: none · 2021: 1 paper · 2022: 2 papers · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper

Papers 19

  1. Repositioning of aripiprazole, an anti‑psychotic drug, to sensitize the chemotherapy of pancreatic cancer. Last author DOI 10.3892/ijmm.2024.5458↗
  2. Tumor Stroma as a Therapeutic Target for Pancreatic Ductal Adenocarcinoma. Last author DOI 10.4062/biomolther.2024.029↗
  3. Vactosertib, TGF-β receptor I inhibitor, augments the sensitization of the anti-cancer activity of gemcitabine in pancreatic cancer. Last author DOI 10.1016/j.biopha.2023.114716↗
  4. A Serum Marker for Early Pancreatic Cancer With a Possible Link to Diabetes. First author DOI 10.1093/jnci/djab191↗
  5. Combination Therapy of the Active KRAS-Targeting Antibody inRas37 and a PI3K Inhibitor in Pancreatic Cancer. Last author DOI 10.4062/biomolther.2021.145↗
  6. Intracellular KRAS-specific antibody enhances the anti-tumor efficacy of gemcitabine in pancreatic cancer by inducing endosomal escape. Last author DOI 10.1016/j.canlet.2021.03.015↗
  7. An Integrative Data Mining and Omics-Based Translational Model for the Identification and Validation of Oncogenic Biomarkers of Pancreatic Cancer. Co-author DOI 10.3390/cancers11020155↗
  8. A novel tropomyosin-related kinase A inhibitor, KK5101 to treat pancreatic cancer. Last author DOI 10.1016/j.canlet.2018.03.041↗
  9. KRAS targeting antibody synergizes anti-cancer activity of gemcitabine against pancreatic cancer. Last author DOI 10.1016/j.canlet.2018.09.013↗
  10. Synthesis of Gemcitabine-Threonine Amide Prodrug Effective on Pancreatic Cancer Cells with Improved Pharmacokinetic Properties. Co-author DOI 10.3390/molecules23102608↗
  11. Oncolytic adenovirus expressing relaxin (YDC002) enhances therapeutic efficacy of gemcitabine against pancreatic cancer. Last author DOI 10.1016/j.canlet.2017.03.009↗
  12. Corrigendum to "Oncolytic adenovirus expressing relaxin (YDC002) enhances therapeutic efficacy of gemcitabine against pancreatic cancer" [Cancer Lett. 396 (201… Last author DOI 10.1016/j.canlet.2017.06.019↗
  13. Radiosensitization of the PI3K inhibitor HS-173 through reduction of DNA damage repair in pancreatic cancer. Last author DOI 10.18632/oncotarget.22850↗
  14. HS-173, a novel PI3K inhibitor suppresses EMT and metastasis in pancreatic cancer. Last author DOI 10.18632/oncotarget.12871↗
  15. Anticancer activity of HS-527, a novel inhibitor targeting PI3-kinase in human pancreatic cancer cells. Last author DOI 10.1016/j.canlet.2014.07.001↗
  16. HS-104, a PI3K inhibitor, enhances the anticancer efficacy of gemcitabine in pancreatic cancer. Last author DOI 10.3892/ijo.2014.2435↗
  17. Synergistic anticancer activity of HS-173, a novel PI3K inhibitor in combination with Sorafenib against pancreatic cancer cells. Last author DOI 10.1016/j.canlet.2013.01.007↗
  18. Anti-cancer effect of HS-345, a new tropomyosin-related kinase A inhibitor, on human pancreatic cancer. Last author DOI 10.1016/j.canlet.2013.04.002↗
  19. SB365, Pulsatilla saponin D suppresses proliferation and induces apoptosis of pancreatic cancer cells. Last author DOI 10.3892/or.2013.2517↗

Closest collaborators

The 25 strongest of 28 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kyung Hee Jung · 18 shared papers, 2013–2025 · strength 1.73
  2. Hong Hua Yan · 14 shared papers, 2013–2022 · strength 0.92
  3. Mi Kwon Son · 12 shared papers, 2013–2022 · strength 0.77
  4. Zhenghuan Fang · 8 shared papers, 2014–2022 · strength 0.65
  5. Jung Hee Park · 6 shared papers, 2016–2022 · strength 0.50
  6. Yeo Wool Kang · 5 shared papers, 2017–2022 · strength 0.45
  7. Soyeon Ko · 2 shared papers, 2023–2025 · strength 0.37
  8. Ye Jin Cho · 2 shared papers, 2023–2025 · strength 0.37
  9. Sungwoo Hong · 6 shared papers, 2013–2018 · strength 0.32
  10. Yong‐Sung Kim · 3 shared papers, 2018–2022 · strength 0.31
  11. Dae Ui Lee · 1 shared paper, 2024 · strength 0.31
  12. Ji Eun Lee · 4 shared papers, 2017–2021 · strength 0.30
  13. Ji Eun Lee · 2 shared papers, 2022–2023 · strength 0.29
  14. Minhee Park · 1 shared paper, 2025 · strength 0.22
  15. Chae‐Ok Yun · 2 shared papers, 2017 · strength 0.14
  16. Woohyung Lee · 1 shared paper, 2022 · strength 0.13
  17. Sunghyouk Park · 1 shared paper, 2022 · strength 0.13
  18. Hoonsik Nam · 1 shared paper, 2022 · strength 0.13
  19. Soo‐Youl Kim · 1 shared paper, 2022 · strength 0.13
  20. Song Cheol Kim · 1 shared paper, 2022 · strength 0.13
  21. Ye-Lim Ryu · 3 shared papers, 2013–2014 · strength 0.12
  22. Han‐Joo Maeng · 1 shared paper, 2018 · strength 0.10
  23. Nguyen Phuoc Long · 1 shared paper, 2019 · strength 0.08
  24. Sung Won Kwon · 1 shared paper, 2019 · strength 0.08
  25. Marufa Rumman · 1 shared paper, 2016 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.